X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
3.740
-0.070 (-1.84%)
At close: Oct 29, 2025, 4:00 PM EDT
3.769
+0.029 (0.77%)
After-hours: Oct 29, 2025, 7:39 PM EDT
X4 Pharmaceuticals Revenue
X4 Pharmaceuticals had revenue of $1.97M in the quarter ending June 30, 2025, with 250.44% growth. This brings the company's revenue in the last twelve months to $32.77M, up 5,721.31% year-over-year. In the year 2024, X4 Pharmaceuticals had annual revenue of $2.56M.
Revenue (ttm)
$32.77M
Revenue Growth
+5,721.31%
P/S Ratio
0.79
Revenue / Employee
$229,189
Employees
143
Market Cap
83.96M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.56M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 3.00M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
XFOR News
- 2 days ago - X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million - GlobeNewsWire
- 6 days ago - X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering - GlobeNewsWire
- 6 days ago - X4 Pharmaceuticals Announces Proposed Underwritten Public Offering - GlobeNewsWire
- 6 weeks ago - X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership - GlobeNewsWire
- 4 months ago - X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA) - GlobeNewsWire